AR052172A1 - Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares - Google Patents
Inhibicion por arni de ctgf pra el tratamiento de trastornos ocularesInfo
- Publication number
- AR052172A1 AR052172A1 ARP050105371A ARP050105371A AR052172A1 AR 052172 A1 AR052172 A1 AR 052172A1 AR P050105371 A ARP050105371 A AR P050105371A AR P050105371 A ARP050105371 A AR P050105371A AR 052172 A1 AR052172 A1 AR 052172A1
- Authority
- AR
- Argentina
- Prior art keywords
- ctgf
- inhibition
- arni
- treatment
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se aporta interferencia por ARN para la inhibicion de la expresion del ARNm del factor de crecimiento del tejido conectivo en trastornos oculares que involucran la expresion del CTGF. Los trastornos oculares que involucran la expresion del CTGF anormal incluyen glaucoma, degeneracion macular, retinopatía diabética, neovascularizacion coroidal, vítreo retinopatía proliferativa, y cicratrizacion de heridas. Tales trastornos se tratan mediante la administracion de ARN de interferencia de la presente.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63870504P | 2004-12-23 | 2004-12-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052172A1 true AR052172A1 (es) | 2007-03-07 |
Family
ID=36218404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050105371A AR052172A1 (es) | 2004-12-23 | 2005-12-20 | Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares |
Country Status (13)
Country | Link |
---|---|
US (4) | US7622454B2 (es) |
EP (2) | EP1827503A1 (es) |
JP (2) | JP5095414B2 (es) |
KR (1) | KR20070091337A (es) |
CN (1) | CN101160138B (es) |
AR (1) | AR052172A1 (es) |
AU (1) | AU2005319279B2 (es) |
BR (1) | BRPI0516377A (es) |
CA (1) | CA2591611A1 (es) |
MX (1) | MX2007007654A (es) |
TW (1) | TWI386225B (es) |
WO (1) | WO2006069037A1 (es) |
ZA (1) | ZA200704932B (es) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007010608A (es) | 2005-03-11 | 2007-10-19 | Alcon Inc | Inhibicion mediada por i-arn de proteina i relacionada con frizzled para tratamiento de glaucoma. |
US20060275797A1 (en) * | 2005-03-21 | 2006-12-07 | Alcon Manufacturing, Ltd. | Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders |
JP2010540564A (ja) * | 2007-10-01 | 2010-12-24 | アルコン リサーチ, リミテッド | 自己相補的なaavが媒介する眼の障害を処置または予防するための干渉rna分子の送達 |
US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
WO2009065022A2 (en) | 2007-11-15 | 2009-05-22 | Alcon Research, Ltd. | Low density lipoprotein receptor-mediated sirna delivery |
TW200932274A (en) | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
MX2011002143A (es) | 2008-08-25 | 2011-07-20 | Excaliard Pharmaceuticals Inc | Oligonucleotidos antisentido dirigidos contra el factor de crecimiento del tejido conectivo y usos de los mismos. |
ES2657696T3 (es) * | 2008-08-25 | 2018-03-06 | Excaliard Pharmaceuticals, Inc. | Método para reducir la cicatrización durante la curación de una herida utilizando compuestos antisentido dirigidos al CTGF |
EP3336188B1 (en) | 2008-09-22 | 2020-05-06 | Phio Pharmaceuticals Corp. | Reduced size self-delivering rnai compounds |
US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US20120016011A1 (en) * | 2009-03-19 | 2012-01-19 | Merck Sharp & Dohme Corp. | RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
EP2550001B1 (en) | 2010-03-24 | 2019-05-22 | Phio Pharmaceuticals Corp. | Rna interference in ocular indications |
KR20180044433A (ko) * | 2010-03-24 | 2018-05-02 | 알엑스아이 파마슈티칼스 코포레이션 | 진피 및 섬유증성 적응증에서의 rna 간섭 |
KR101249041B1 (ko) * | 2010-04-28 | 2013-03-29 | 포항공과대학교 산학협력단 | 결합조직 성장인자를 이용한 약학적 조성물 |
US9241944B2 (en) * | 2010-06-16 | 2016-01-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for stimulating reepithelialisation during wound healing |
ES2732929T3 (es) | 2010-10-22 | 2019-11-26 | Olix Pharmaceuticals Inc | Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas |
JP2014505666A (ja) | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
KR101697396B1 (ko) * | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자(ctgf)를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법 |
CN102727513B (zh) * | 2011-04-15 | 2014-07-09 | 百奥迈科生物技术有限公司 | 靶向于组织因子基因的小核酸及其用途 |
WO2012161677A1 (en) | 2011-05-20 | 2012-11-29 | Alcon Research, Ltd. | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY |
US8802839B2 (en) * | 2011-07-15 | 2014-08-12 | Fibrogen, Inc. | Connective tissue growth factor antisense oligonucleotides |
US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
CN104244928B (zh) | 2012-01-18 | 2016-08-31 | 株式会社百奥尼 | 磁性纳米颗粒-SAMiRNA复合物及其制备方法 |
ES2716818T3 (es) * | 2012-05-22 | 2019-06-17 | Olix Pharmaceuticals Inc | Molécula de ácido nucleico inductora de interferencias de arn capaz de penetrar en las células y uso de la misma |
RU2670164C2 (ru) | 2013-07-05 | 2018-10-18 | Байонир Корпорейшн | Улучшенная олигонуклеотидная конструкция типа наночастицы, обладающая высокой эффективностью, и способ ее получения |
CA2917318A1 (en) | 2013-07-05 | 2015-01-08 | Bioneer Corporation | Dengue virus related genes-specific sirna, double-stranded oligo rna molecules comprising the sirna, and composition for the inhibition of dengue virus replication comprising the same |
RU2656154C2 (ru) | 2013-07-05 | 2018-05-31 | Байонир Корпорейшн | СВЯЗАННАЯ С РЕСПИРАТОРНЫМ ЗАБОЛЕВАНИЕМ ГЕН-СПЕЦИФИЧЕСКАЯ миРНК, ДВУСПИРАЛЬНАЯ КОНСТРУКЦИЯ ОЛИГО-РНК, СОДЕРЖАЩАЯ миРНК, И СОДЕРЖАЩАЯ ЕЕ КОМПОЗИЦИЯ ДЛЯ ПРЕДУПРЕЖДЕНИЯ ИЛИ ЛЕЧЕНИЯ РЕСПИРАТОРНОГО ЗАБОЛЕВАНИЯ |
EP3077050B1 (en) * | 2013-12-04 | 2020-10-21 | Phio Pharmaceuticals Corp. | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
CN106459974A (zh) | 2014-04-04 | 2017-02-22 | 柏业公司 | 新颖的双链寡rna和包含它的用于预防或治疗纤维化或呼吸系统疾病的药物组合物 |
US11279934B2 (en) | 2014-04-28 | 2022-03-22 | Phio Pharmaceuticals Corp. | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11565023B2 (en) | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
US10314690B1 (en) * | 2014-05-12 | 2019-06-11 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
CN107852029B (zh) | 2015-05-04 | 2022-05-27 | 科罗拉多州立大学董事会公司实体 | 无线电力传输 |
KR20180071362A (ko) | 2015-11-16 | 2018-06-27 | 올릭스 주식회사 | MyD88 또는 TLR3을 타겟팅하는 RNA 복합체를 이용한 연령-관련 황반 변성의 치료 |
US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
KR20180104075A (ko) | 2016-02-02 | 2018-09-19 | 올릭스 주식회사 | IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료 |
KR20180104692A (ko) | 2016-02-02 | 2018-09-21 | 올릭스 주식회사 | Angpt2 및 pdgfb를 표적화하는 rna 복합체를 사용하는 혈관신생 관련 질환의 치료 |
US10301628B2 (en) | 2016-04-11 | 2019-05-28 | Olix Pharmaceuticals, Inc. | Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor |
KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
CN110770343A (zh) | 2017-02-10 | 2020-02-07 | 成均馆大学校产学协力团 | 用于rna干扰的长双链rna |
US10363833B2 (en) * | 2017-03-15 | 2019-07-30 | Ford Global Technologies, Llc | Inductive charging active suspension |
KR20190037166A (ko) * | 2017-09-28 | 2019-04-05 | 올릭스 주식회사 | 결합 조직 성장 인자를 표적으로 하는 rna 복합체를 함유하는 노인성 황반변성의 예방 또는 치료용 약학 조성물 |
EP3831392A4 (en) * | 2018-07-31 | 2022-08-17 | Lemonex Inc. | COMPOSITION FOR INHIBITING CTGF EXPRESSION |
US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
CN110144350A (zh) * | 2019-05-15 | 2019-08-20 | 基诺泰康生物科技(北京)有限公司 | 一种特异性抑制CTGF基因表达的siRNA及其在抑制癜痕形成中的应用 |
KR20210063137A (ko) | 2019-11-22 | 2021-06-01 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
EP4159858A1 (en) * | 2020-05-26 | 2023-04-05 | Olix Pharmaceuticals, Inc. | Rnai agent targeting myd88 and use thereof |
CN114807127A (zh) * | 2021-01-19 | 2022-07-29 | 陈璞 | 用于结缔组织生长因子的小干扰rna及其应用 |
WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7384634B2 (en) | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
US5408040A (en) | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
JPH08501928A (ja) * | 1992-07-02 | 1996-03-05 | ハイブライドン インコーポレイテッド | 治療剤としての自己安定化オリゴヌクレオチド |
US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
US7041548B1 (en) * | 1996-07-16 | 2006-05-09 | Micron Technology, Inc. | Methods of forming a gate stack that is void of silicon clusters within a metallic silicide film thereof |
US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
US6348329B1 (en) | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
EP1272630A2 (en) | 2000-03-16 | 2003-01-08 | Genetica, Inc. | Methods and compositions for rna interference |
ES2336887T5 (es) | 2000-03-30 | 2019-03-06 | Whitehead Inst Biomedical Res | Mediadores de interferencia por ARN específicos de secuencias de ARN |
EP1873259B1 (en) | 2000-12-01 | 2012-01-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA interference mediated by 21 and 22nt RNAs |
JP4779255B2 (ja) | 2001-07-16 | 2011-09-28 | パナソニック株式会社 | レーザ光源 |
EP1463531B1 (en) * | 2001-12-11 | 2011-09-28 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
AU2003221762B2 (en) | 2002-04-30 | 2008-09-25 | Alcon, Inc. | Agents which regulate, inhibit or modulate the activity and/or expression of connective tissue growth factor (CTGF) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
PT1504126E (pt) | 2002-05-03 | 2014-06-02 | Univ Duke | Um método para regular a expressão génica |
AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
EP1534832A2 (en) | 2002-09-04 | 2005-06-01 | Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
WO2004031237A1 (en) * | 2002-09-30 | 2004-04-15 | Oncotherapy Science, Inc. | Genes and polypeptides relating to human myeloid leukemia |
US20040175732A1 (en) | 2002-11-15 | 2004-09-09 | Rana Tariq M. | Identification of micrornas and their targets |
CA2513623A1 (en) | 2003-01-16 | 2004-08-05 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of icam-1 |
AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
WO2004096277A1 (ja) * | 2003-05-01 | 2004-11-11 | Kyoto University | 眼内血管新生疾患の予防又は治療剤 |
US7462602B2 (en) * | 2003-05-01 | 2008-12-09 | University Of Florida Research Foundation, Inc. | Anti-scarring ribozymes and methods |
AU2004242586C1 (en) * | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
GB0404209D0 (en) | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
-
2005
- 2005-11-24 TW TW094141307A patent/TWI386225B/zh not_active IP Right Cessation
- 2005-12-19 JP JP2007548380A patent/JP5095414B2/ja not_active Expired - Fee Related
- 2005-12-19 EP EP05857141A patent/EP1827503A1/en not_active Withdrawn
- 2005-12-19 MX MX2007007654A patent/MX2007007654A/es active IP Right Grant
- 2005-12-19 KR KR1020077016318A patent/KR20070091337A/ko not_active Application Discontinuation
- 2005-12-19 EP EP10010890A patent/EP2319543A1/en not_active Withdrawn
- 2005-12-19 CN CN2005800479231A patent/CN101160138B/zh not_active Expired - Fee Related
- 2005-12-19 US US11/313,200 patent/US7622454B2/en not_active Expired - Fee Related
- 2005-12-19 CA CA002591611A patent/CA2591611A1/en not_active Abandoned
- 2005-12-19 BR BRPI0516377-3A patent/BRPI0516377A/pt not_active IP Right Cessation
- 2005-12-19 WO PCT/US2005/046064 patent/WO2006069037A1/en active Application Filing
- 2005-12-19 AU AU2005319279A patent/AU2005319279B2/en not_active Ceased
- 2005-12-19 ZA ZA200704932A patent/ZA200704932B/xx unknown
- 2005-12-20 AR ARP050105371A patent/AR052172A1/es unknown
-
2009
- 2009-10-12 US US12/577,267 patent/US7838507B2/en not_active Expired - Fee Related
-
2010
- 2010-10-08 US US12/901,019 patent/US20110028534A1/en not_active Abandoned
-
2012
- 2012-02-14 JP JP2012029499A patent/JP2012097119A/ja not_active Withdrawn
-
2013
- 2013-12-05 US US14/097,928 patent/US20140094502A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN101160138B (zh) | 2013-05-15 |
US20060166919A1 (en) | 2006-07-27 |
EP1827503A1 (en) | 2007-09-05 |
AU2005319279A1 (en) | 2006-06-29 |
CN101160138A (zh) | 2008-04-09 |
JP2008525460A (ja) | 2008-07-17 |
ZA200704932B (en) | 2008-11-26 |
CA2591611A1 (en) | 2006-06-29 |
EP2319543A1 (en) | 2011-05-11 |
BRPI0516377A (pt) | 2008-09-02 |
KR20070091337A (ko) | 2007-09-10 |
US20140094502A1 (en) | 2014-04-03 |
AU2005319279B2 (en) | 2011-08-18 |
TWI386225B (zh) | 2013-02-21 |
WO2006069037A1 (en) | 2006-06-29 |
US7838507B2 (en) | 2010-11-23 |
TW200626721A (en) | 2006-08-01 |
JP2012097119A (ja) | 2012-05-24 |
MX2007007654A (es) | 2007-11-09 |
US20110028534A1 (en) | 2011-02-03 |
JP5095414B2 (ja) | 2012-12-12 |
US20100035969A1 (en) | 2010-02-11 |
US7622454B2 (en) | 2009-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052172A1 (es) | Inhibicion por arni de ctgf pra el tratamiento de trastornos oculares | |
CR10041A (es) | Uso de vías inhibitorias coplementarias para el tratamiento de enfermedades oculares | |
UY30058A1 (es) | (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa | |
MX2021006092A (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos. | |
ES2495965T3 (es) | Uso de derivados 2,5-dihidroxibencénicos para el tratamiento de enfermedades oculares | |
CO2020014563A2 (es) | Uso de clorhidrato de pilocarpina para el tratamiento de condiciones oculares | |
Elbaz et al. | Accelerated versus standard corneal collagen crosslinking combined with same day phototherapeutic keratectomy and single intrastromal ring segment implantation for keratoconus | |
NZ705624A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
AR056852A1 (es) | INHIBICIoN DE HIF1A INTERMEDIADO POR RNAI PARA EL TRATAMIENTO DE ANGIOGENESIS OCULAR | |
De Keyser et al. | Selective laser trabeculoplasty as replacement therapy in medically controlled glaucoma patients | |
Taylor et al. | Intravitreal methotrexate in uveitis | |
CL2023001596A1 (es) | Composiciones y métodos para el tratamiento de enfermedades oculares | |
TN2019000112A1 (en) | Ophthalmic formulation comprising citicoline carried by liposome for the treatment of glaucoma | |
AU2018240462A1 (en) | Drugs and compositions for the treatment of ocular disorders | |
Letko et al. | UVA-light and riboflavin-mediated corneal collagen cross-linking | |
Iu et al. | An update of treatment options for neovascular age-related macular degeneration | |
Richoz et al. | Corneal cross-linking as an adjuvant therapy in the management of recalcitrant deep stromal fungal keratitis: a randomized trial | |
MD581Y (en) | Method for treatment of senile cataract associated with pseudoexfoliative syndrome | |
MX2020011535A (es) | Formulacion de gotas para ojos y metodos para la liberacion sostenida de medicamento a la retina. | |
CL2011001812A1 (es) | Uso de deferiprona para prevenir yotratar un trastorno ocular relacionado con hierro seleccionado de : degeneracion macular relacionada con la edad, glaucoma, cataratas, retinopatía diabetica, degeneración hereditaria de la retina, desprendiimiento de la retina, retinopatía isquémica, entre otras. | |
Nicula et al. | Corneal collagen cross-linking in keratoconus–Long-term prospective study | |
Kamil et al. | Comparison of conjunctival autograft and intra-operative application of mitomycin-C in treatment of primary pterygium | |
US20210023384A1 (en) | Non-invasive cornea and sclera strengthening device and method | |
BR112022009192A2 (pt) | Composição, método para tratar uma doença ocular ou distúrbio ocular, e, uso de um composto | |
RU2496457C1 (ru) | Способ защиты роговицы и лимбальной зоны глаза от воздействия ультрафиолетового излучения при кросслинкинге |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |